Will Eli Lilly stock hold the $1,356 support as sellers dominate after price drop?

Traders Union
All News
Stocks
Eli Lilly drops 3.2% to $1,371

Highlights

Eli Lilly revenue surged 53% in volume to $24.4 billion in the third quarter, with annual revenue guidance raised to $91 to $92 billion.
Eli Lilly distributed $1.5 billion in dividends and executed $400 million in share repurchases, while intensifying legal action to defend its weight loss drug franchise.
Shares of Eli Lilly closed down 3.2% at $1,371 amid strong intraday selling, with technicals indicating a sideways price range of $1,356 to $1,387 over the next 2 to 3 days.

Guidance boost and franchise defense amid profit-taking pressures

Eli Lilly reported strong third-quarter 2026 results on October 29, with revenue reaching $24.4 billion and worldwide volume increasing 53%, even as realized prices fell 15%, according to Seeking Alpha and TradingKey. The company also raised its annual revenue guidance to $91–92 billion, reflecting confidence in sustained demand and ongoing growth at scale. During the third quarter, Eli Lilly returned $1.5 billion to shareholders through dividends and completed $400 million in share repurchases, as noted by Yahoo Finance. Legal and regulatory action continued as the company intensified pressure on providers of compounded Tirzepatide+ weight loss drugs and forced changes to a competitor's advertising strategy, moves aimed at protecting Eli Lilly's key franchises — though price action has remained under broader selling pressure.

Momentum mixed as oscillators warn of possible overheating

On the technical front, LLY/USD is trading below the MA-20 and MA-50 on the hourly chart, while remaining above the MA-200 on the daily timeframe. Immediate resistance is set by the Ichimoku Kijun at $1,405, with support positioned at $1,356. Among indicators, MACD shows a strong buy signal, ADX and the Awesome Oscillator are neutral, and Bull/Bear Power remains strongly positive, reflecting ongoing buyer activity intraday. RSI is neutral, while both Stochastic RSI and CCI are in overbought territory, highlighting potential for near-term overheating but not confirming a reversal.

Sideways range expected as upside risk outweighs breakdown

Over the next 2–3 trading days, LLY is expected to trade between $1,356 and $1,387, representing its typical volatility band relative to current levels. The baseline scenario anticipates sideways consolidation. If price breaks above immediate resistance at $1,405, a bullish move could develop, while a failure of support at $1,356 would open the path for further declines. The probability of an upward move is assessed at 59%, making a downward move less likely in the short term.

Viktoras Karapetjanc, Traders Union expert, sees fundamental strength in Eli Lilly’s raised guidance and strong Q3 revenue, despite near-term pressure from lower realized prices. He believes the company’s legal efforts and robust shareholder returns reinforce its growth outlook. The technical setup points to consolidation with a slight bullish tilt. Karapetjanc states, "Positive demand trends and decisive corporate actions make me constructive on Eli Lilly, especially if price can reclaim resistance at $1,405."

Earlier, analysts noted that Eli Lilly’s strong earnings and raised revenue guidance were supporting a bullish bias, although technical signals warned of overbought conditions and possible downside risk. With the current move below key moving averages and downside momentum in play, traders should watch support at $1,356 as a break below this level could prompt increased volatility and further weakness in the near term.

Source of Data: LLY Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.